Patent application number | Description | Published |
20110022899 | PRODUCING OR EXECUTING A SCRIPT FOR AN OPERATION TEST OF A TERMINAL SERVER - A method of or system for producing or executing a script for a load test of a terminal server. During execution of a high-level application by the terminal server controlled by a user of a terminal client in which the terminal client and terminal server communicate according to remote-desktop protocol, a terminal-services agent on the terminal server may monitor a change in at least one window of the high-level application within a terminal-client desktop of the terminal client. Window-related information corresponding to the monitored change from the terminal-services agent may be sent to an operation-test tool resident on the terminal client. The operation-test tool may log the received window-related information. | 01-27-2011 |
20120096185 | METHODS, SYSTEMS, AND APPARATUS FOR PROCESSING MESSAGING DATA SETS USING STRUCTURED DATA SETS - In one embodiment, a plurality of data conversion modules are bound to a processing engine and a first messaging data set is provided to a conversion module from the plurality of conversion modules. The messaging data set conforms to a messaging format. A structured data set based on a first data portion and a second data portion of the first messaging data set are received and value different from the value of the first data portion is stored within a first element of the structured data set. The value of the second data portion is stored within a second data element of the structured data set. A second messaging data set is then generated based on the structured data set. | 04-19-2012 |
20130077817 | STEGANOGRAPHIC METHOD - A steganographic method is presented that provides authentication of user identity, such that only an authorized user may reveal the data hidden steganographically. Two data objects such as images are used for this purpose, one hidden within the other. A key provision of the invention allows the ‘inner’ image to itself contain hidden data that is not corrupted by subsequent compression within the ‘outer’ image. A digital ‘scratch card’ is by this means implemented, where the inner image is only revealed to an authorized user. Using this algorithm, physical cards containing data are represented by a single digital object. | 03-28-2013 |
Patent application number | Description | Published |
20090181028 | B-CELL EPITOPE PEPTIDES OF HSP 65, NOVEL AMINO ACID SEQUENCES, DNA ENCODING THE AMINO ACID SEQUENCES OF SAID PEPTIDES, ANTIBODIES DIRECTED AGAINST SAID PEPTIDES AND DIFFERENT USES THEREOF IN THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES - B-cell epitope peptides of HSP 65, particularly the peptides comprising the amino acid sequence substantially as denoted by SEQ ID: NOs. 1-5 and their biologically functional homologues and derivatives thereof. Also included are polyclonal and monoclonal antibodies directed against them and their compositions for passive immunization against inflammatory and autoimmune diseases and in the treatment of inflammatory and autoimmune diseases. Also encompassed are diagnostic uses of these antibodies, for identifying people at risk of developing arthritis or diabetes, and a method of monitoring progress of the disease conditions and disease prognosis. | 07-16-2009 |
20100285146 | PEPTIDES AND METHODS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS - A method is disclosed for treating systemic lupus erythematosus in a mammalian subject, comprising administering to said subject an effective dose of at least one laminin peptide, or an analog or a derivative thereof. In one exemplary embodiment, the laminin peptide is selected from the group consisting of R38 (SEQ. ID. NO. 1), and claimed R38 analogs and derivatives thereof including 5200 (SEQ. ID. NO. 10), 5104 (SEQ. ID. NO. 15), 5105 (SEQ. ID. NO. 16), 5106 (SEQ. ID. NO. 17), 5107 (SEQ. ID. NO. 18), 5108 (SEQ. ID. NO. 19), 5109 (SEQ. ID. NO. 20), 5110 (SEQ. ID. NO. 21). The laminin peptides of the present invention may be prepared by known chemical synthetic methods or by biotechnological methods. The invention also provides assays useful for the diagnosis of and following pathological activity course of systemic lupus erythematosus in patients suffering therefrom. In addition, the subject invention concerns a method of treating systemic lupus erythematosus in a subject comprising the extracorporeal removal of lupus antibodies from the subject's plasma and returning the plasma to the subject. In an additional aspect, the invention provides method of reducing anti-R38 antibody levels in a patient's plasma. | 11-11-2010 |
20120014973 | ADENYLYL CYCLASE-ASSOCIATED PROTEIN (CAP1) AND USES THEREOF AS A TARGET FOR IMMUNO-MODULATION - The present invention relates to the use of Adenylyl Cyclase-Associated Protein (CAP1) as a target for immuno-modulation. More specifically, the invention relates to the use of compounds that interact and bind CAP1, specifically, anti-CAP1 antibodies, and/or to CAP1 molecule or any fragments thereof, for the treatment of immune-related disorders by modulation of the Th1/Th2 balance. The invention further provides screening method for immuno-modulatory compounds that interact with CAP1. | 01-19-2012 |
20120076753 | USE OF NKP46 FOR PREVENTING DIABETES - The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes. | 03-29-2012 |
20120156201 | HUMANIZED ANTIBODIES SPECIFIC FOR HSP65-DERIVED PEPTIDE-6 METHODS AND USES THEREOF - The present invention relates to humanized antibodies that specifically bind a polypeptide comprising peptide-6 as denoted by SEQ ID NO. 15, that is an HSP65 derived peptide. More specifically, the invention relates to humanized anti-peptide-6 antibodies, compositions, methods and uses thereof for the treatment of immune-related disorders, specifically, inflammatory disorders such as arthritis, IBD, psoriasis, diabetes and MS. The invention further provides combined compositions and kit combining the humanized antibodies of the invention and at least one anti-inflammatory agent, as well as uses of the humanized antibodies in diagnostic kits and methods. | 06-21-2012 |
20130280209 | METHOD FOR TREATING TYPE 1 DIABETES - The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes. | 10-24-2013 |
20140170138 | HUMANIZED ANTIBODIES SPECIFIC FOR HSP65-DERIVED PEPTIDE-6, METHODS AND USES THEREOF - The present invention relates to humanized antibodies that specifically bind a polypeptide comprising peptide-6 as denoted by SEQ ID NO. 15, that is an HSP65 derived peptide. More specifically, the invention relates to humanized anti-peptide-6 antibodies, compositions, methods and uses thereof for the treatment of immune-related disorders, specifically, inflammatory disorders such as arthritis, IBD, psoriasis, diabetes and MS. The invention further provides combined compositions and kit combining the humanized antibodies of the invention and at least one anti-inflammatory agent, as well as uses of the humanized antibodies in diagnostic kits and methods. | 06-19-2014 |